Senti Biosciences Holdings, Inc. (SNTI)
0.3903
0.00 (0.00%)
USD |
NASDAQ |
Aug 26, 15:39
Senti Biosciences Holdings Debt to Equity Ratio : -5.947 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | -5.947 |
| March 31, 2026 | 7.462 |
| December 31, 2025 | 5.169 |
| September 30, 2025 | 3.709 |
| June 30, 2025 | 1.270 |
| March 31, 2025 | 0.857 |
| December 31, 2024 | 0.6628 |
| September 30, 2024 | 2.170 |
| June 30, 2024 | 0.8096 |
| March 31, 2024 | 0.6547 |
| December 31, 2023 | 0.5629 |
| Date | Value |
|---|---|
| September 30, 2023 | 0.4499 |
| June 30, 2023 | 0.3925 |
| March 31, 2023 | 0.3391 |
| December 31, 2022 | 0.2915 |
| September 30, 2022 | 0.2429 |
| June 30, 2022 | 0.2001 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.3765 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| NovelStem International Corp. | -0.8748 |
| Brainstorm Cell Therapeutics, Inc. | -0.1185 |
| Summit Therapeutics, Inc. | 0.0324 |
| Kezar Life Sciences, Inc. | 0.0208 |
| Protara Therapeutics, Inc. | 0.017 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 33.10M |
| Total Liabilities (Quarterly) | 36.51M |
| Shareholders Equity (Quarterly) | -3.401M |
| Current Ratio | 0.8251 |
| Net Debt Paydown Yield | 7.13% |